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Abstract 
Antidepressant-like Effects of Amisulpride, Ketamine, and Their Enantiomers on Differential-
Reinforcement-of-Low-Rate (DRL) Operant Responding in Male C57BL/6 Mice 
By Douglas A. Smith 
A thesis submitted in partial fulfillment of the requirements for the degree of  
Master of Science at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2017 
Director: Joseph H. Porter, PhD 
Professor of Psychology, Department of Psychology 
 
Major depressive disorder (MDD) is a widespread psychiatric disorder that affects millions of 
people worldwide and is hypothesized to occur due to impairments in several neurotransmitter 
systems, including the monoaminergic and glutamatergic neurotransmitter systems. 
Antidepressant medications targeting multiple monoamine neurotransmitters have been shown to 
be effective for the treatment of depression. Racemicamisulpride is an atypical antipsychotic that 
has been used at low doses to treat dysthymia, a mild form of depression, and functions as an 
antagonist at DA2/3, 5-HT2B, and 5-HT7 receptors. Recent preclinical studies have suggested that 
the S(+)isomer may be more critical for amisulpride‘s antidepressant-like effects; however, this 
interpretation has not been fully characterized in comparison to the R(-)isomer. The 
glutamatergic system also has been shown to play a critical role in alleviating depression. 
Several studies have demonstrated that the noncompetitive N-methyl-D-aspartate (NMDA) 
receptor antagonist ketamine produces rapid and sustained antidepressant-like effects in clinical 
trials; however, few studies have examined the degree to which ketamine‘s isomers contribute to 
antidepressant-like effects. Fully characterizing these differences in a preclinical model of 
depression may offer important insight into the role of these neurotransmitter systems on 
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depression. The present study used a 72-sec differential-reinforcement-of-low-rate (DRL) task to 
assess the antidepressant-like effects of amisulpride, ketamine, and their isomers in mice. The 
DRL 72-sec task has shown to be a reliable and sensitive screen for drugs that possess 
antidepressant-like activity as reflected by an increase in the number of reinforcers, a decrease in 
the number of responses, and a right-ward shift in the interresponse time distributions (IRTs; i.e. 
the elapsed time between two successive responses). For comparison, the effects of the tricyclic 
antidepressant imipramine and the N-methyl-D-aspartate antagonist MK-801 as positive and 
negative controls, respectively, were determined. Consistent with previous findings, we 
hypothesized that amisulpride and S(-)-amisulpride, but not R(+)-amisulpride, would produce 
antidepressant-like effects, andall formulations of ketamine would produce antidepressant 
effects. Racemic amisulpride and S(-)-amisulpride, but not R(+)-amisulpride, produced an 
antidepressant-like effect, evidenced by a significant increase in the number of reinforcers and a 
significant decrease in the number of responses. Racemic ketamine and R(-)-ketamine 
significantly increased the number of reinforcers and decreased the number of responses, while 
S(+)-ketamine significantly increased the number of reinforcers, but did not decrease the number 
of responses (at the doses tested). Overall, these results indicate that the racemic formulations of 
amisulpride and ketamine, S(-)-amisulpride, and both ketamine isomers demonstrate 
antidepressant-like effects as assessed in the DRL task and may be useful in a clinical context. If 
either of the ketamine isomers can be shown to produce fewer psychotomimetic effects in 
humans, then the isomers may offer a significant clinical advantage over the parent compound 
ketamine. Regarding amisulpride, the present results demonstrate that the S(-) isomer, but not the 
R(+)isomer, possess antidepressant-like activity similar to racemic amisulpride. 
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Introduction 
Major depressive disorder (MDD) is a widespread psychiatric disorder that affects 
millions of people worldwide. Per a report from the World Health Organization (2014), 
depression accounts for nearly 5% of the total worldwide burden of diseases. MDD worsens the 
health of patients with other chronic illnesses, such as chronic pain and respiratory diseases, and 
is associated with increasing disability over time. In addition to the psychological harm to the 
individual, MDD also negatively impacts both economic and occupational public health 
(Greenberg et al., 2003; Fostick et al., 2010). For instance, Fostick and colleagues (2010) posited 
that the economic costs to US society due to MDD is estimated to be over $83 billion when 
factoring in costs due to the pharmacological and behavioral treatments of depression, loss of 
work and productivity, and suicide-related mortality costs. Moreover, it has been hypothesized 
that treatment-resistant depression (TRD; patients who do not respond to two or more 
antidepressant treatments) affects 20-40% of those suffering from MDD (Sackeim, 2001); 
however, about half of the patients that do show a reduction of depressive symptoms with their 
first treatment have significant residual symptoms. Thus, only about 20-40% of patients are 
expected to reach a relative stable asymptotic state after their first treatment.These 
epidemiological findings suggest that MDD is a major public health risk that negatively impacts 
psychological, economic, and societal factors.  
MDD is characterized as a chronic affective disorder comprised of behavioral 
abnormalities, including negative affect, insomnia, suicidal ideation, significant impairments to 
social and occupational functioning, and manifests in neurobiological abnormalities (Fava, 2003; 
Fava and Kendler, 2000; Nestler et al., 2002). Per the National Comorbidity Survey, the lifetime 
prevalence of MDD as defined by the American Psychiatric Association‘s Diagnostic and 
2 
 
Statistical Manual of Mental Disorders V (DSM-V; criteria summarized in Table 1) 
criteria was estimated at 17%, while 5% of the population reported meeting criteria for MDD in 
the last 30 days (Fava and Kendler, 2000). While depressive episodes may appear at any age, 
MDD is most prevalent in adults (18-64 years old) (Kessler, 2012). In addition, females are two-
to-three times more likely to be diagnosed with MDD than their male counterparts (Kessler, 
2012).  While MDD is one of the most common psychiatric disorders in the United States, the 
exact cause and most efficacious treatment options have remained elusive.  
Monoamine and Glutamate Theories of Depression 
Monoamine Theory of Depression: Historically, MDD has been hypothesized to be caused by 
genetic, environment, and psychological factors that eventually manifest into behavioral and 
neurobiological impairments (Table 1; Belmaker, 2008). Before the early 1950s, the best 
treatment option for depression was electroconvulsive shock therapy. Later, medication 
development became widespread after the serendipitous finding that pharmacological 
compounds improve mental disorders through central nervous system activity, beginning with 
the discovery of chlorpromazine.  
In 1950, the French chemist Paul Charpentier synthesized 4560 RP, now known as 
chlorpromazine. Within two years, chlorpromazine was shown to produce relaxation in surgical 
patients and produce decreased manic states in schizophrenic patients (Anton-Stephens, 1954). 
However, the first documented use of chlorpromazine in psychiatry was in a patient named 
Jacques Lh, a 24-year-old severely agitated psychotic male. After 20 days of being treated with 
50 mg chlorpromazine, along with barbiturates and electroshocks, Hamon and colleagues (1952) 
discharged Jacques Lh, and he resumed normal life. Taken together, these early findings were 
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the first reports demonstrating that pharmacological agents may be useful for the treatment of 
psychosis.   
 
Table 1. American Psychological Association‘s Diagnostic and Statistical Manual V criteria for 
Major Depressive Disorder.  
 
The monoamine hypothesis of depression posits that individuals suffering from 
depression have depleted levels of the monoamine neurotransmitters serotonin (5-HT), dopamine 
(DA), and norepinephrine (NE) (Bunney and Davis, 1965; Hirschfeld, 2000). Evidence 
supporting the monoamine hypothesis began with the discovery that the vesicular monoamine 
transporter inhibitor reserpine produced a depletion of serotonin and other monoamines in the 
brain, and this depletion led to depressive-like symptoms in humans that could be relieved by 
discontinuation of the drug (Shore et al., 1995; Shore et al., 1957). Later, preclinical studies 
demonstrated that reserpine produced depressive-like effects in animals (Hirchfield, 2000). 
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Another supportive finding for the monoamine hypothesis was based on the antidepressant-like 
effects produced by imipramine, a tricyclic antidepressant (TCA), which acts by blocking the 
serotonin transporter (SERT) and norepinephrine transporter (NET) resulting in an elevation of 
synaptic concentrations of these neurotransmitters. This finding spurred further interest in 
medications that function by monoamine oxidase inhibition (MAOI). The first MAOI that was 
shown to produce antidepressant effects was iproniazid (Julien, 2013). While originally intended 
for the treatment of tuberculosis, it was also shown to produce relief from depression. Later, in 
vitro studies demonstrated that iproniazid produced these antidepressant effects through 
inhibition of monoamine oxidase (West and Dally, 1959). Monoamine oxidase is an enzyme that 
normally metabolizes and regulates the amount of the biogenic amine transmitters in the 
presynaptic nerve terminal, namely NE, DA, and 5-HT (Julien, 2013). Thus, administration of 
iproniazid increases the levels of these neurotransmitters and more transmitter is available for 
release when stimulated by an action potential reaching the nerve terminals, resulting in robust 
antidepressant action. Functionally, inhibition of MAO leads to higher concentrations of 
monoamines in the synaptic cleft, thereby prolonging the activity of these monoamines and 
producing a reduction in depressive symptoms (Wells and Bjorksten, 1989). Together, the 
findings that both the tricyclic imipramine and the MAO inhibitor iproniazid increased 
monoamine neurotransmitter levels at the synapse led to the monoamine hypothesis of 
depression. Despite these landmark findings of drugs for the treatment of depression, it was soon 
realized that these first-generation antidepressants had neurotoxic effects (Hindmarch, 2002). 
While TCAs exhibited a slow onset of action, limited efficacy across different 
populations of depressed patients, sexual and metabolic side effects, the MAOIs were found to 
produce hypertensive issues, especially when taken with certain foods and other medications 
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(Meyer et al., 2006). For instance, the trace amine tyramine, which also induces release of 
monoamine neurotransmitters, is found in many foods, including cheese, wine, beans, and liver. 
When combined with MAOIs, excessive levels of tyramine may cause an elevated rise in blood 
pressure, resulting in a possible heart attack or rupture of an aneurism or vascular formation 
(Prus, 2013). Due to these adverse side effects, there was interest in developingnovel, less toxic, 
antidepressant drugs. Nonetheless, discovery of the antidepressant effects of TCAs and MOAIs 
was important for the treatment of depression and led to the monoamine hypothesis of 
depression.  
After the negative side effects of these first-generation antidepressants were recognized, a 
second generation of antidepressants were developed (Julien, 2013). Examples of the second 
generation of antidepressants included selective serotonin reuptake inhibitors (SSRIs; fluoxetine, 
citalopram, sertraline, etc.) and selective serotonin and norepinephrine reuptake inhibitors 
(SSNRIs; e.g. duloxetine). The first second-generation antidepressant drug was introduced to the 
United States market in the 1980s, when bupropion (a norepinephrine-dopamine reuptake 
inhibitor) was approved for the treatment of MDD, followed by the SSRI fluoxetine (Julien, 
2013). In general, what sets the second generation of antidepressants apart from the first 
generation is that they more selectively inhibit the reuptake of 5-HT at the presynaptic neuronal 
membrane. In addition, the second-generation antidepressant drugs have comparable efficacy, 
comparable or better side effect profiles, and are better tolerated than the first-generation 
antidepressants (Heninger et al., 1996). 
Despite these findings that the monoamine neurotransmitter system is an important factor 
in MDD (based on the pharmacological mechanisms of the drugs used to treat MDD), this theory 
has some major flaws. First, there are drugs that can increase brain monoaminergic activity, such 
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as cocaine or amphetamine, but are not effective clinically as antidepressants (Millan 2004). 
Second, not all depressed patients respond equally well to the same antidepressant, suggesting 
individual differences such as genetics or environment also play a critical role (Elhwuegi, 2004). 
Third, the changes in the monoamine levels at the synapse take place within minutes or hours 
after administration of antidepressants, but the therapeutic response requires weeks of repeated 
administration (Millan, 2004). These flaws in the monoamine hypothesis soon led to a modified 
hypothesis that posited acute increase in the levels of the monoamines at the synapse may be the 
initial step which then leads to a cascade of events downstream that result in antidepressant 
activity. However, this cascade of events considers many other neurotransmitter receptor 
systems, notably the glutamatergic N-methyl-D-aspartate (NMDA) receptors. This revised 
theory for the role of monoamines ultimately states that monoamines may play a modulatory 
role, which led to investigation of other neurotransmitter systems that may play a role in the 
pathogenesis of MDD.  
Glutamate Theory of Depression: As early as the 1990s, inconsistencies in the monoamine 
hypothesis regarding the pathophysiology of depression led to studies examining the role of the 
glutamatergic neurotransmitter system. Glutamate is the major excitatory neurotransmitter in the 
central nervous system (Oreggo and Villanueva, 1993), and the earliest study on the glutamate 
theory of depression can be traced back to an early study that showed NMDA antagonists 
produced antidepressant-like action (Trullas and Skolnick, 1990). Sanacora et al. (2012) 
demonstrated that there are approximately two to three hundred thousand serotonergic neurons 
out of a hundred billion total neurons in the brain, and about 80% of neurons in the neocortex are 
excitatory and form 85% of the synapses (Sanacora et al., 2012). These data indicate that 
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glutamatergic neurons and synapses far outnumber all the other neurotransmitter systems in the 
brain and suggest that the glutamate system also may play an important role in depression.  
Glutamate acts on two types of receptors, ionotropic and metabotropic. Ionotropic 
glutamatergic receptors include AMPA, kainate, and NMDA receptors. These receptors are ion 
channels that are permeable to cations and function by allowing sodium (Na) and calcium (Ca) 
ions to enter the cell, thus causing depolarization and other intracellular changes (Kew and 
Kemp, 2005). Eight subtypes of metabotropic glutamate receptors (mGluR1-8) are divided into 
Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3), and Group III (mGluR4,6,7, 
8) based upon their homology and function. These glutamatergic receptors are G-protein-coupled 
receptors (GPCRs) and function by influencing intracellular second messenger formation (Kew 
and Kemp 2005). NMDA receptors are a specific type of ionotropic glutamate receptors. These 
receptors are a heteromeric complex that have seven subunits, NR1, NR2A-D, and NR3A-B and 
functional NMDA receptors must be comprised of an NR1 subunit and at least one NR2 subunit. 
To be activated, NMDA receptor channels require co-agonist binding at the glycine binding site 
on the NR1 subunit and at the glutamate binding site on the NR2 subunit (Kew and Kemp, 2005; 
Marsden 2013). Thus, if one of these co-agonists (glycine or glutamate) is not bound to their 
respective binding site, the ion channel will not open. Also, the NMDA receptor channels are 
blocked by magnesium (Mg) ions during the resting state. Depolarization of the neuron is 
required to dispel the Mg ion from the NMDA receptor channels, which is usually achieved by 
activation of AMPA receptors. The NMDA receptor ion channel is non-selective and will allow 
both Na and Ca to enter. The influx of Ca is associated with the induction of various signaling 
cascades (Marsden, 2013).  
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Clinical evidence for glutamatergic dysfunction in depression has been demonstrated in 
plasma, cerebrospinal fluid, and brain tissue of individuals with mood disorders, and 
antidepressant drug treatment has been found to reduce the serum glutamate (Maes et al., 1998), 
cerebrospinal fluid (Garakani et al., 2013), and plasma glutamine/glutamate concentrations in 
MDD patients (Küçükibrahimoğlu et al., 2009). Multiple studies also have reported elevated 
glutamate levels, and a trend for decreased plasma glutamine/glutamate ratios in the plasma of 
depressed patients compared to healthy controls (Kim, 1982; Altamura, 1993; Mitani, 2006). 
Other studies have provided evidence that treatment with antidepressant agents may decrease the 
plasma glutamate levels in depressed individuals (Altamura et al., 1995, Maes et al., 1998). 
Furthermore, a postmortem study of the frontal cortex showed a significant increase in tissue 
glutamate levels in individuals with major depressive and bipolar disorders after controlling for 
postmortem interval (Hashimoto et al., 2007). Consistent with this finding, an analysis of 
postmortem dorsolateral prefrontal cortex tissue revealed elevated glutamate levels in bipolar 
individuals (Lan et al., 2009). Studies also have shown that MDD patients have a greater 
sensitivity to glutamate as measured by intracellular calcium influx (Berk et al., 2001).  
Collectively, these findings suggest that the glutamatergic system plays an important role 
in the pharmacology of antidepressant-like drugs. Since the discovery of the importance of 
glutamatergic neurotransmission in MDD, both the monoamine and glutamatergic hypotheses 
have led to a better understanding of the neurochemical, physiological, and behavioral correlates 
of MDD.  
Preclinical Models of Depression 
Preclinical models have been useful for understanding how monoaminergic- and 
glutamatergic-based medications produce antidepressant-like effects. Different-reinforcement-of-
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low-rate operant responding (DRL), the forced-swim test (FST), tail suspension test (TST), and 
learned helplessness paradigms have been widely utilized to measure antidepressant-like effects 
in animals. However, each of these procedures have positive and negative methodological 
considerations that impact their applicability as models of depression.  
Learned Helplessness in Depression: From a historical perspective, one of the first landmark 
findings in preclinical models of depression emerged from Martin Seligman‘s work on learned 
helplessness. Seligman (1972) described learned helplessness as a condition in which the subject 
is administered repeated aversive stimuli and is unable to escape. After repeated pairings with an 
aversive stimulus, the animals eventually will become immobile and will not escape even when 
escape is presented to them. This finding quickly led to the learned helplessness theory which 
posits that clinical depression may result from the perceived absence of control over the outcome 
of a situation. To show evidence for this theory, Seligman and colleagues used an escape 
avoidance shuttle box in dogs. Here, the dog is administered repeated electrical shock to the floor 
of one side of the shuttle box. Eventually, the dogs learned to escape to the other side of the 
shuttle box that did not have an electrical floor. However, after repeated trials, he observed that 
some dogs would not attempt to escape and would endure the electrical shock. He hypothesized 
that this maladaptive behavior was the underlying cause of clinical depression in humans. This 
behavior is defined by a reduced response mechanism and negative cognitive set (difficulty in 
learning that one‘s own response will succeed). This behavior has also been translated to other 
species, including rats, cats, fish, and humans (Seligman, 1972). In addition, Seligman has 
observed three behaviors from learned helplessness experiments. First, response initiation is 
compromised, which is the probability the subject will initiate responses to escape is lower 
because part of the incentive for making such responses is the expectation that they will bring 
10 
 
relief.  Second, retardation of learning is evident from the subject learning that responding and 
shock are independent. Third, the subject learns that trauma is uncontrollable, which may 
produce emotional stress rather than learning that it is controllable. While this theory provides 
important insight into the behavioral consequences underlying depression, learned helplessness 
has been criticized for not distinguishing between cases in which outcomes are uncontrollable for 
all people and cases in which they are uncontrollable only for some people (i.e. universal vs. 
personal helplessness), and it does not explain when helplessness is general and when specific, or 
chronic and acute.  
Forced Swim Test: The forced swim test (FST) is one of the most commonly used preclinical 
animal models to screen antidepressant drugs, developed by Porsolt and colleagues in 1977. In 
this procedure, rats were placed into a cylinder of water from which they cannot escape and are 
forced to swim. After an initial intense escape-directed behavior, the rats would eventually 
become immobile, making only those movements necessary to keep their head above water. 
Porsolt et al. (1977) hypothesized that this period of immobility was a preclinical proxy of 
‗behavioral despair‘ and represented hopelessness in the animal. Subsequent tests with different 
doses of the TCAs imipramine, desipramine, amitriptyline, and the MAOI nialamide reduced 
immobility in a biphasic manner, where a certain dose produced a maximal effect and 
lower/higher doses produced less immobility. They also tested drugs from other drug classes, 
including anxiolytics, stimulants, and tranquilizers, which did not produce this antidepressant 
effect. These findings established the FST as a reliable screening tool for antidepressant drugs.  
Although there are different methodological manipulations to this procedure, Porsolt et 
al. (1977) measured immobility in rats during a 15-min pretest session to measure baseline levels 
of immobility. After 24 hours, the animal was then placed in the FST chamber and immobility 
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was again measured for a 5-min test session. Typically, drugs are administered before the test 
session and any changes in immobility are recorded. Nearly forty years later, this procedure is 
still widely used to assess the effectiveness of antidepressant drugs by pharmaceutical industries 
and scientific researchers in both rats and mice.  
Despite its widespread use and validation as a preclinical assay for measuring the 
antidepressant-like activity of drugs, the FST has a wide range of positive and negative 
indications as a scientific procedure (Petit-Demouliere et al., 2005). First, the FST is an effective 
preclinical assay for measuring the antidepressant-like activity of drugs in that it generally 
satisfies both the empirical model (experimental conditions in which known antidepressants 
exert pharmacological effects not shared by other therapeutic classes of drugs) and theoretical 
model (translatability to reproduce in animals the human symptomatology of a disorder) of 
depression (Borsini and Meli, 1988). Other major advantages of the FST in comparison to other 
preclinical models of depression include high interlaboratory reliability, high throughput (i.e. 
data can be obtained rapidly), data are clearly conveyed and interpretation is straightforward, and 
it does not require the use of complex equipment, thus reducing costs. Moreover, the validity and 
translatability of the FST procedure as a preclinical model of depression is not without 
controversy. For instance, the ―behavioral despair‖ interpretation of immobility has been 
questioned due to the lack of an established relationship between inescapability and immobility, 
since rats are less fearful on subsequent immersion than on previous ones, which suggests that 
behavioral immobility is a consequence of an adaptive response to a stressful situation more than 
―despair‖ (Hawkins et al. 1978). Similarly, Borsini and Meli (1988) showed that familiarity with 
the environment rather than ―despair‖ may induce behavioral immobility. Another disadvantage 
to the FST as a model of depression is that stimulants, sedatives, and drugs that induce motor 
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impairment can lead to false-negative or false positive results (Slattery and Cryan, 2012). 
Furthermore, one major side effect of most antidepressants is sedation; however, data derived 
from the FST do not distinguish sedative effects from antidepressant properties of drugs. These 
examples are reflective of a major limitation in that many established tests are influenced by 
drugs that modulate the general activity of the animal being tested. Lastly, a major criticism of 
the FST is that antidepressant-like effects are interpreted from acute administration of 
antidepressant drugs, but many of the antidepressant drugs in clinical use take weeks to provide 
alleviation of depressive symptoms. While this criticism can be applied to other preclinical 
models of depression, this disconnect between the antidepressant-like effects regarding acute and 
chronic drug administration illustrates a lack of translatability for the FST as a preclinical model 
of depression in humans.   
Tail Suspension Test: The tail suspension test is another procedure used as a model for assessing 
antidepressant activity. In this procedure, an animal (most studies have used rodents) is 
suspended by their tail, causing a short-term stress response (Porsolt et al., 1977). Eventually, the 
animal will develop an immobile posture, somewhat like the immobile behavior an animal 
exhibits in the forced swim test. Studies have shown that when antidepressant medications are 
administered before the TST, they will actively persist in escape-directed behaviors for longer 
periods of time than after vehicle treatment.  
Advantages of this procedure are that the entirety of the procedure is quite short, since the 
actual session takes about 5 minutes. Other advantages of this procedure are its ability to detect a 
broad spectrum of antidepressant drug effects irrespective of their underlying mechanism, it is 
inexpensive, methodologically unsophisticated, and easily amenable to automation.  
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Like the criticism of the forced swim test, the tail suspension test is a measure of acute drug 
effects, even though antidepressant medications take weeks until antidepressant effects are 
exhibited. This procedure is also very sensitive to species differences. For instance, some strains 
of mice will try to climb their tail to escape, instead of going immobile, so caution must be 
exercised in interpreting species differences. Finally, the tail suspension test also produces false 
positives and false negatives, similar to the FST (Steru et al., 1985).   
Differential Reinforcement of Low Rate (DRL): The differential-reinforcement-of-low-rate 
(DRL) task is an operant conditioning method, wherein a subject must withhold an operant 
response for a specified amount of time in order to obtain a reinforcer. In preclinical research, 
laboratory animals are typically trained to press a lever (operant response), and only responses 
that exceed a predetermined interval result in delivery of a reinforcer. Over the course of 
training, the animal learns to limit operant responses and eventually produce a frequency 
distribution of interresponse times (IRTs) that peaks near the DRL criterion interval (Fowler et 
al., 2009), and previous results from our research program have shown that IRTs peak at 36-37 
seconds (Hillhouse & Porter, 2014). Responses emitted prior to fulfillment of the DRL criterion 
result in no reinforcer and a reset in the IRT requirement. The DRL procedure has been used in 
human and laboratory animals to examine 1) timing behavior, 2) impulsivity and attention-
deficit/hyperactivity disorder (Bull et al. 2000; Andrzejewski, 2014), 3) neural substrates of 
timing behavior (Chiang, 2015), 4) pharmacological effects on temporal processing (Cho et al., 
2010), and 5)as a preclinical screen for antidepressant-like effects (Fowler et al., 2009). Studies 
examining antidepressant medication using the 72-second DRL task have shown that a wide 
variety of antidepressant drugs produce an antidepressant-like effect, evidenced byan increase in 
reinforcers, a decrease in responses, and a rightward shift in the peak location of the IRT 
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distribution (O‘Donnell et al., 2005). These effects are hypothesized to be indicative of 
antidepressant-like drug action because 1) antidepressant drugs target serotonin receptor 
subtypes to alleviate symptoms which is the main neurotransmitter system implicated in 
depression and antipsychotic medication treatments, 2) since impulsivity is correlated with 
higher rates of depression, antidepressant drugs may selectively decrease impulsivity in 
laboratory animals, and 3) temporal discrimination is thought to play a role in depression and 
impulsivity (O‘Donnell et al., 2005).  
Studies suggest that longer DRL intervals affect behavior through mediation of 
serotonergic mechanisms, since administration of most antidepressant and antipsychotic drugs in 
laboratory animals leads to a decrease in responses and an increase in rewards. The 72-sec DRL 
task has been utilized extensively as a preclinical drug screening tool for serotonin-selective 
reuptake-inhibitors, tricyclic antidepressants, typical and atypical antipsychotics, all of which 
target serotonin systems (O‘Donnell et al., 2005). Thus, drugs that exhibit selectivity for 
inhibition of serotonin uptake, improve performance in rodents trained on a 72-sec DRL interval. 
Studies have shown that most antidepressant drugs increase reinforcement rate, decrease 
response rate, and shift the IRT distribution to the right; whereas, other drugs such as caffeine, 
opioids, barbiturates, ethanol, and anticholinergics have mixed results on DRL behavior 
depending on species used, age of animal, dose of drug, and different environmental parameters 
used in different studies (O‘Donnell et al., 2005). Furthermore, amphetamine, cocaine, and other 
monoaminergic-type drugs decrease reinforcement rate, increase response rate, and shift the IRT 
distribution to the left (O‘Donnell et al., 2005), producing an amphetamine-like effect in the 
DRL task. These findings indicate that the DRL 72-sec IRT is selectively sensitive to 
antidepressant drug effects relative to most other drug classes.  
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 Considering the positive and negative features of each of these preclinical assays, the 
DRL 72-sec taskhas two major advantages:first, this procedure has not been shown to produce 
false positives as seen in the FST and TST assays;second, the DRL 72-sec task is selectively 
sensitive to antidepressant-like drug effects(O‘Donnell et al., 2005).  
Ketamine and Amisulpride 
Ketamine: Ketamine is a dissociative anesthetic with hallucinogenic properties that is a 
derivative of phencyclidine (PCP). Originally developed by Dr. Calvin Lee Stevens at Wayne 
State University for the pharmaceutical company Parke-Davis in 1964, ketamine was shown to 
produce anesthetic, sedative, and analgesic properties in humans and animals. After being 
approved by the Food and Drug Administration for use as a short-acting anesthetic in 1970, 
ketamine became a widely-used treatment for both American soldiers during the Vietnam War 
(Domino, 2010) and veterinary applications under the trade names Ketalar, Ketaset, and 
Vetamine. While ketamine continues to be useful in human and veterinary medicine, it was 
classified as a Schedule III substance in 1999 under the Controlled Substances Act due to 
recreational use for its hallucinogenic properties at high doses (DEA, 2013). Ketamine, known as 
―Special K,‖ was shown to elicit hallucinogenic-like dissociative (perceptual distortions) effects 
and exhibited profound effects on psychological functioning, resulting in feelings of 
depersonalization (detachment from the ‗body and self‘) and derealization (detachment from the 
‗environment and reality‘). However, ketamine also has been shown to have therapeutic effects 
for heroin addiction (Krupitsky et al., 2002) and as a rapid-acting antidepressant for MDD 
(Lapidus et al., 2014). Finally, due to the similarities between the acute pharmacological effects 
of ketamine and the behavioral impairments observed in schizophrenic patients, researchers have 
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used ketamine and its analogs to characterize the neurobiological determinants of schizophrenia 
(Lahti et al., 1995).  
 
Figure 1. Chemical structures for racemic ketamine, S(+)-ketamine, and R(-)-ketamine (chemical 
structures obtained from Zhang et al., 2014).  
 
Mechanistically, ketamine is an N-methyl-D-aspartate (NMDA) noncompetitive 
antagonist (channel blocker) that primarily affects the glutamatergic system by binding to 
allosteric sites on NMDA receptors. Allosteric sites are specific sites on the receptor protein 
where a molecule acts to inhibit or activate the receptor without affecting the active site (agonist 
site) of the receptor for the endogenous neurotransmitter. In this way, ketamine binds to the PCP 
site inside the NMDA receptor ion channel and is nonselective for the NR2A-D subunits of the 
NMDA receptor channel (Lord et al., 2013; Yamakura et al., 1993; Yamakura et al., 1999). 
Studies have shown that ketamine is 12-20-fold more selective for NMDA receptors as 
compared to serotonin 5-HT2A and mu opioid receptors (Kapur and Seeman, 2002), has binding 
affinity for sigma, muscarinic, and opioid (Kappa and sigma) receptors (Hillhouse et al., 2014), 
and DA, NE, and 5-HT receptors (Moghaddam et al., 1997; see Table 2 for binding affinities).  
Ketamine is the racemic mixture (optically inactive) of two enantiomers of equal 
quantity, the S(+) and R(-) isomers (molecules with the same formula but different arrangement 
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of atoms, chemical structure, and rotate light in opposite ways; Figure 1). The S(+)-ketamine 
enantiomer (―S‖ spatial structure, light rotated to the right) is approximately two times more 
potent than the racemic form and four times more potent than the R(-)-ketamine isomer (―R‖  
spatial structure, light rotated to the left). Interestingly, one preclinical study has shown that the 
R(-)-ketamine stereoisomer shows greater potency and longer lasting antidepressant-like effects 
than the S(+)-stereoisomer on depression-like behavior in juvenile mice after neonatal 
dexamethasone exposure in the tail suspension test and the forced swim test (Zhang et al., 2014). 
Receptor Ligand Racemic 
ketamine 
 
S(+)-ketamine R(-)-ketamine 
     
NMDA (1) 
 
[3H]MK-801 0.53 (nM) 0.30 (nM) 1.40 (nM) 
Mu opioid (2) 
 
[3H]DAGO 2.5 (nM) 11 (nM) 28 (nM) 
Sigma (2) [3H]DPDPE 1.0 (nM) 130 (nM) 130 (nM) 
     
Kappa (2) [3H]U69593 4.2 (nM) 24 (nM) 100 (nM) 
     
PCP (2) [3H]TCP 2.9 (nM) 1.1 (nM) 3.2 (nM) 
     
Omega (2) [3H]+SKF10,047 0.15 (nM) 131 (nM) 19 (nM) 
     
Muscarinic (2) [3H]QNB 1.8 (nM) 20 (nM) 37 (nM) 
     
     
Table 2. NMDA binding affinities for racemic ketamine, S(+)-ketamine, and R(-)-ketamine. Data 
from Ebert et al. (1997) (1 – ligand was MK801) in the rat cortex. All others are adapted from 
Hustveit et al. (1995) (in guinea pig brain homogenate) 
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Pharmacokinetic studies have shown that ketamine has a low binding affinity to plasma 
proteins, has extensive distribution due to its high lipid solubility, and is metabolized by the 
liver, kidneys, the intestine, and lungs (Idvall et al., 1979). Because of N-demethylation, 
ketamine is mostly metabolized to norketamine (80%), an active metabolite that is itself 
principally hydroxylized to 6-hydroxy-norketamine (15%), and is excreted in bile and urine. 
Ketamine elimination clearance is high (1000-1600 ml/min or 12-20 ml/min/kg) and elimination 
half-life is 2-3 hours in humans. The S(+) isomer demethylation is more pronounced to that of 
the R(-) isomer and has a higher distribution volume. Studies have shown that the R(-) isomer 
inhibits S(+) isomer demethylation to a proportion of 30%, while S(+) isomer in turn inhibits R(-
) metabolism. However, functional differences in enantiomers are essentially due to 
pharmacodynamic effects since their cerebral and blood concentrations are similar in humans 
(White et al., 1985).  
Functional magnetic resonance imaging has shown that plasma concentrations of 200 
ng/ml of ketamine in humans correlates with reduced pain scores, decreased levels in insular 
cortex and thalamic activity, and is activated by nociceptive stimulation (Mion et al., 2013). 
Intravenous S(+)-ketamine at doses of 0.05-0.15 mg/kg/h dose dependently decreased pain 
perception and decreased activation of the secondary somatosensory cortex, insula, and anterior 
cingulate cortex, which has been linked to the affective pain component that underlies the 
potency of ketamine in modulating affective pain processing (Arendt-Nielson et al., 1996). 
Several studiesalso have demonstrated that the medial reticular formation, which processes pain 
perception, is depressed, as well as the medial thalamic nuclei (Klepstad et al., 1990). 
Interestingly, it has also been shown that ketamine enhances the descending inhibiting 
serotonergic pathway (Pekoe, 1982).  
19 
 
Amisulpride: Amisulpride (Amazeo, Amival, Solian) was developed in the 1990s by Sanofi-
Aventis as an atypical antipsychotic used to treat psychosis in schizophrenia and mania in bipolar 
disorder (Rozenweig, 2002) and is also clinically approved for the treatment of schizophrenia 
and dysthymia, a mild form of depression, in multiple European countries. One previous study 
showed that amisulpride was as effective as imipramine and fluoxetine in terms of treating 
depression in humans as measured by the Montgomery and Asberg Depression Rating Scale 
(MADRS) (Perrault et al., 1997). In another study, amisulpride demonstrated significantly 
greater improvement in severely depressed patients compared to haloperidol and risperidone 
(Peuskens et al., 2002). 
 
Figure 2. Chemical structures for racemic amisulpride, S(-)-amisulpride, and R(+)-amisulpride.    
(Chemical structures drawn by E.O. De Oliveira) 
 
Amisulpride is a benzamide derivative and has been shown to produce both antipsychotic 
and antidepressant-like effects (Perrault et al., 1997) and has been shown to be a selective 
antagonist at dopamine D2 and D3 receptors and serotonin 5-HT2B and 5-HT7 receptors 
(Shoemaker et al., 1996). Amisulpride is a chiral molecule composed of two optical isomers: (S)-
amisulpride and (R)-amisulpride, which in combination form the therapeutic drug, rac-
amisulpride (see Figure 2 for chemical structures). (S)-amisulpride is more potent than racemic 
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amisulpride and (R)-amisulpride and is hypothesized to be responsible for the antipsychotic and 
antidepressant-like effects of amisulpride (Shoemaker et al., 1997; Perrault et al., 1997). It has 
been shown that amisulpride blocks the synthesis and release of dopamine by targeting 
presynaptic neurons, and at high doses, it has been suggested that the occupancy and antagonism 
of D2 receptors is more critical to itsmechanism of action (Schoemaker et al., 1996). However, 
the antagonismof 5-HT7a receptors is hypothesized to be responsible for amisulpride‘s 
antidepressant efficacy (Abbas et al., 2009). In addition, it also has been shown that the S(+) 
stereoisomer is twice as potent at D2/3 receptors twice than the racemic form and 30 times more 
potent than the R(-) isomer (Castelli, et al., 2001). In human studies, it has been shown that 
amisulpride treatment (up to 100 mg/kg) resulted in alleviation of negative symptoms in 
schizophrenia (Danion et al. 1999). In contrast, it has been shown that lower doses of 
amisulpride (50 mg/kg) is useful for the treatment of dysthymia (Rocca et al. 2002). These 
antidepressant effects have been hypothesized to occur by pre-synaptic blockade of DA 
receptors, which then increases DA release, while the antipsychotic effects are thought to be due 
to blockade of post-synaptic DA receptors (Rosenzweig et al. 2002; see Table 3 for binding 
affinities). However, the therapeutic efficacy of each individual enantiomer has not been 
determined and requires further testing. 
Drug 5-HT2A  
(rat striatum) 
Ki(nM)+S.E.M. 
D2 
(rat cortex) 
Ki(nM)+S.E.M. 
Alpha-2 
(rat cortex) 
Ki(nM)+S.E.M. 
    
Rac-amisulpride >5000 9.8+-0.4 783+-27 
S(-)-amisulpride >5000 5.2+-0.1 1528+-45 
R(+)-amisulpride  >5000      244+-12 375+-14 
Table 3. Binding affinities for racemic amisulpride, S(-)-amisulpride, and R(+)-amisulpride. Data 
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from Marchese et al., (2002). Data represent mean (+-S.E.M) of four independent experiments.  
 
Hypotheses and Rationale 
Since the therapeutic efficacy of each individual enantiomer has not been determined for 
both amisulpride and ketamine, the specific aims of this study were to characterize the 
antidepressant-like effects of amisulpride, ketamine, and their optical isomers using the DRL 72-
sec IRT in mice. The TCA imipramine will be used as a positive control, the NMDA agonist 
MK-801 as a negative control, and amisulpride and ketamine racemic formulations and their 
isomers as our test compounds. Imipramine is a tricyclic antidepressant and has been shown to 
improve performance on longer DRL schedules, while MK-801 is a psychostimulant which has 
been shown to impair performance on DRL schedules. We hypothesize that imipramine and 
amisulpride will increase reinforcers, decrease responses, and shift the IRT distribution to the 
right. We also hypothesize that MK-801 will decrease reinforcers, increase responses, and shift 
the IRT distribution to the left. Since previous literature indicates that the S-stereoisomer for 
amisulpride and the R-stereoisomer for ketamine are responsible for antidepressant-like 
effects,we hypothesized that both enantiomers will produce antidepressant-like effects. In 
contrast, we do not expect to observe antidepressant-like activity (or reduced activity) with the 
R-stereoisomer for amisulpride and S-stereoisomer for ketamine Thus, these results will add 
important information about the antidepressant-like behavioral effects of amisulpride and 
ketamine using a preclinical model in C57BL/6 mice.  
Furthermore, we chose to use C57BL/6 mice in this study because all previous studies 
have only used rats. Using mice would help determine any potency or species differences on the 
antidepressant-like effects induced by amisulpride, ketamine, and their enantiomers.  
22 
 
Methods 
Subjects and apparatus:Twenty-six adult male C57BL/6 mice (Envigo, Indianapolis, IN) 
weighing 20-28 grams were used as subjects. All mice were acclimated to normal laboratory 
handling and free feeding weights. After acclimation to laboratory conditions, daily access to 
food was restricted to maintain the mice at 85-90% of their free feeding body weights, and water 
was continuously available except during testing and training DRL sessions (approximately 
12:00 to 16:00 daily). All animals were housed individually in plastic cages in the temperature-
controlled vivarium (22
O
 C) with a 12h/12h light/dark cycle (light on at 7:00 AM) and all 
behavioral sessions were conducted during the light cycle. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth 
University (IACUC protocol AM10215), and all procedures were conducted in accordance with 
National Institutes of Health Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, 2011).  
Testing was conducted in six standard computer-interfaced operant conditioning 
chambers (15 cm L X 11.5 cm D X 17.5 cm H; Model ENV-307A, Med Associates Inc., St. 
Albans, VT) housed inside sound attenuating cubicles equipped with ventilation fans and a house 
light. Each operant box was composed of a grid floor constructed of parallel stainless steel rods 
and two retractable levers were positioned on the front panel of the operant chamber (8cm apart) 
which extended 0.8 cm into the chamber. A dipper was located between the two levers that 
delivered 0.03 ml of sweetened milk (Sam‘s West, Inc. Bentonville, AR). 
Drugs:(S)-amisulpride, (R)-amisulpride, and racemic amisulpride hydrochloride were donated by 
Dr. de Oliveira(Department of Chemical & Life Science Engineering, Virginia Commonwealth 
University, Richmond, VA), andimipramine (positive control), MK-801 (dizocilpine; negative 
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control), and all formulations of ketaminewere bought from Sigma Aldrich Chemical Company 
(St. Louis, Missouri). All drugs were distilled in 0.9 saline. All injections were administered 
subcutaneously (s.c.) and the injection volume was 10 ml/kg body weight.Drug doses and 
injection times were determined from previously published research (Hillhouse and Porter, 2014; 
Donahue et al., 2014). The order in which the drugs were tested are shown in figure3. 
Procedure: All mice were weighed before each behavioral session and maintained at 85-90% of 
their free feeding body weight. All mice were first given one session of magazine training during 
which the house light was on, but the levers were not extended into the chamber. During 
magazine training, one reinforcer (0.03 ml of sweetened condensed milk) was delivered from a 
liquid dipper located in between the retractable levers every 5 seconds to acclimate them to the 
dipper, which remained in the up position for 5 seconds. All responses were then reinforced 
according to a fixed ratio (FR) 1 schedule of reinforcement for three sessions, in which each 
lever press resulted in delivery of a reinforcer. The position of the lever associated with the FR 1 
schedule was counterbalanced across animals, with half of the mice assigned to the right lever 
and half assigned to the left lever. Following completion of the FR 1 schedule training, all mice 
began DRL training.  
During DRL training, a response produced a reinforcer only after a specified inter-
response interval had elapsed. Responses emitted before the end of the inter-response interval 
reset the timer and did not produce a reinforcer. The inter-response interval was gradually 
increased from an initial value of 4.5s to a terminal value of 72s over approximately 30 sessions. 
Specifically, mice were initially trained on a DRL 4.5s schedule for three sessions. Next, the 
DRL schedule was increased to 9s for five sessions, 18s for 10 sessions, 36s for 20 sessions, and 
the final 72s DRL criterion until performance stabilized. DRL performance was considered 
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stable when the number of responses for each mouse did not vary by more than 10% of the mean 
for five of six consecutive sessions.  
During the testing phase, mice were run 4-5 days per week, consisting of at least two 
baseline sessions and 1-2 test sessions. If mice baseline data varied by more than 10% of the 
mean for at least two baseline sessions, they were excluded from testing until baseline 
performance was stable. The drugs,dose ranges, and pretreatment timeswere as follows: racemic 
amisulpride (1.0-32.0 mg/kg; 60 min), R(+)-amisulpride (10.0-56.0 mg/kg; 60 min), S(-)-
amisulpride (3.2-10.0 mg/kg; 60 min), racemicketamine (3.2-10 mg/kg; 10 min), R(-)-ketamine 
(5-10 mg/kg; 10 min), S(+)-ketamine (2.5-5 mg/kg; 10 min), (+)-MK-801 (negative control; 
0.01-0.1; 15 min), and imipramine (positive control; 3.2-17.8 mg/kg; 60 min).  
Data analysis: The dependent variables include (a) total number of earned reinforcers during 
each test session, (b) total number of responses during each test session, (c) IRTs for all 
responses during each test session. All data are expressed as means (+/-SEM) unless otherwise 
noted. Reinforcer and response data were analyzed using a one-way repeated-measures analysis 
of variance (ANOVA), followed by Dunnett‘s post hoc test to compare all drug doses to vehicle. 
Only main effects for the number of reinforcers, number of responses, and IRT distributions are 
reported.The IRT distributions were obtained by recording responses in 25 6-sec bins, with the 
first 6-sec bin representing ‗burst responding.‘ To determine whether there was a shift in the IRT 
distribution, a peak location analysis was performed, whereby the median of the IRT distribution 
for each mouse was determined after eliminating burst responses from the total number of 
responses. Medians were analyzed using one-way repeated-measures ANOVA for dose [for 
more information on IRT analysis, see Richards et al. (1993)]. For the IRT graphs, the relative 
frequency for each 6-sec bin was found for each mouse (total number of responses divided by 
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number of responses for each time bin) and then averages were calculated for each time bin. The 
criterion for significance was set at the 95% confidence level(P<0.05), and all data were 
analyzed using GraphPad Prism version 7.0 for Windows (GraphPad Software, San Diego, 
California, USA).  
Results 
DRL training and baseline performance: All mice met the DRL training criterion in a mean of 
27.4 (+4.6) training sessions. To determine whether the vehicle baselines changed throughout the 
study, data from the vehicle baselines for imipramine, amisulpride and its stereoisomers, 
ketamine and its stereoisomers, and MK-801 were analyzed for the number of reinforcers and 
number of responses with separate one way ANOVAs. For number of reinforcers, there was no 
statistically significant main effect [F(7, 83) = 0.705, p = 0.67]. For number of responses, there 
was no statistically significant main effect [F(7, 83) = 0.62, p = 0.74].  Thus, vehicle baselines 
did not significantly change for any of the drugs during the study (see Figure 3). 
Imipramine and MK-801: For number of reinforcers (Figure 4, top panel), imipramine produced 
a significant main effect of dose [F(3,45)=6.41,p< 0.001], and Dunnett‘s post hoc test revealed 
that the number of reinforcers was significantly increased by the 17.8 mg/kg dose of imipramine 
relative to vehicle (p < 0.05). For number of responses (Figure 4, bottom panel), imipramine 
produced a significant main effect of dose [F(3,45)=5.30,p= 0.003], and Dunnett‘s post hoc test 
revealed that the number of responses was significantly decreased by the 17.8 mg/kg dose of 
imipramine compared to vehicle (p <0.01). A dose of 32 mg/kg induced cataleptic behavior in 
six mice so further testing was discontinued.  
For number of reinforcers, MK-801 (Figure 5, top panel) produced a significant main 
effect of dose [F(2,22)= 18.65,p< 0.0001], and Dunnett‘s post hoc test revealed that the number 
26 
 
of reinforcers was significantly decreased by the 0.1 mg/kg dose of MK-801 relative to vehicle 
(p < 0.05). For number of responses (Figure 5, bottom panel), MK-801 produced a significant 
main effect of dose [F(2,22)= 3.48,p= 0.048], and Dunnett‘s post hoc test revealed that the 
number of responses was significantly increased by the 0.1 mg/kg dose of MK-801 compared to 
vehicle (p < 0.05). A dose of 0.32 mg/kg was administered to six mice but induced rapid 
jumping and hyperactivity so further testing was discontinued. 
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Figure 3. Effects of vehicle baselines on mean number of reinforcers (top; n = 26) and number of 
responses (bottom; n = 26) for all test drugs.  
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Figure 4. Effects of imipramine on mean number of reinforcers (top; n=16) and number of 
responses (bottom; n=16). Asterisks represent significant differences from vehicle, and all data 
are expressed as means +SEM (p < 0.05). For all graphs, *p < 0.05, **p < 0.01, ***p < 0.001,  
and ****p < 0.0001.    
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Figure 5. Effects of MK-801 on mean (+SEM) number of reinforcers (top; n=12) and number of 
responses (bottom; n=12). See Figure 4 for other details. 
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Racemic amisulpride and its enantiomers 
For number of reinforcers (Figure 6, top panel), racemic amisulpride produced a 
significant main effect for dose [F(6,90)=7.88, p<0.0001)]. Compared with other doses of 
racemic amisulpride, Dunnett‘s post hoc test revealed that the 17.8, 32, and 56 mg/kg doses 
produced significant increases in the number of reinforcers compared to vehicle. For number of 
responses (Figure 6, bottom panel), racemic amisulpride produced a significant main effect of 
dose [F(6, 90)=2.56,p= 0.025], and Dunnett‘s post hoc test revealed that the 56.0 mg/kg dose 
produced a small but significant (p <0.05) decrease in responses relative to vehicle. 
For number of reinforcers (Figure 7, top panel), R(+)-amisulpride did not produce a 
significant main effect of dose [F(3,21)= 1.06, p = 0.39]. For number of responses (Figure 7, 
bottom panel), R(+)-amisulpride did not produce a significant main effect of dose 
[F(3,21)=1.02,p= 0.40].  
For number of reinforcers (Figure 8, top panel), S(-)-amisulpride produced a significant 
main effect of dose [F(3,24) = 5.94, p = 0.003]. Compared with other doses of S(-)-
amisulpride,Dunnett‘s post-hoc test revealed that the 10.0 mg/kg dose was significantly different 
than vehicle (p < 0.05). For number of responses (Figure 8, bottom panel), S(-)-amisulpride did 
not produce a significant main effect of dose [F(3,24)=0.24,p= 0.87].  
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Figure 6. Effects of racemic amisulpride on mean (+SEM) number of reinforcers (top; n=16) and 
number of responses (bottom; n=16). See Figure 4 for other details. 
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Figure 7. Effects of R(+)-amisulpride on mean (+SEM) number of reinforcers (top; n=8) and 
number of responses (bottom; n=8). See Figure 4 for other details. 
  
33 
 
S ( - ) - a m i s u l p r i d e  R e i n f o r c e r s
S ( - ) - a m i s u l p r i d e D o s e  ( m g / k g )
M
e
a
n
 N
u
m
b
e
r
 o
f
  
R
e
in
f
o
r
c
e
r
s
V
E
H
1
. 0
3
. 2
1
0
. 0
0
2
4
6
8
1 0
* *
V E H
1 . 0
3 . 2
1 0 . 0
 
S ( - ) - a m i s u l p r i d e  R e s p o n s e s
S ( - ) - a m i s u l p r i d e D o s e  ( m g / k g )
M
e
a
n
 N
u
m
b
e
r
 o
f
  
R
e
s
p
o
n
s
e
s
V
E
H
1
. 0
3
. 2
1
0
. 0
0
1 0 0
2 0 0
3 0 0
V E H
1 . 0
3 . 2
1 0 . 0
 
Figure 8. Effects of S(-)-amisulpride on mean (+SEM) number of reinforcers (top; n=9) and 
number of responses (bottom; n=9). See Figure 4 for other details. 
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Racemic ketamine and its enantiomers 
For number of reinforcers (Figure 9, top panel), racemic ketamine produced a significant 
main effect of dose [F(2,22)=14.82,p< 0.0001], and compared with other doses of racemic 
ketamine, Dunnett‘s post-hoc test revealed that the 10.0 mg/kg dose was significantly different 
than vehicle (p < 0.05). For number of responses (Figure 9, bottom panel), racemic ketamine 
produced a significant main effect of dose [F(2,22) = 14.13, p < 0.0001)]. The Dunnett‘s post 
hoc test revealed that both the 3.2 and 10.0 mg/kg dose were significantly different than vehicle 
(p < 0.05). 
For number of reinforcers (Figure 10, top panel), R(-)-ketamine produced a significant 
main effect of dose [F(2,16)=11.88,p< 0.0007], and Dunnett‘s post-hoc test revealed that the 
10.0 mg/kg dose was significantly different than vehicle (p < 0.05). For number of responses 
(Figure 10, bottom panel), R(-)-ketamine produced a significant main effect of dose 
[F(2,16)=5.38,p= 0.016], and Dunnett‘s post-hoc test revealed that the 10.0 mg/kg dose was 
significantly different than vehicle (p < 0.05). 
For number of reinforcers (Figure 11, top panel), S(+)-ketamine produced a significant 
main effect of dose [F(2,16)=9.83,p< 0.001]. Compared to other doses of S(+)-ketamine, 
Dunnett‘s post hoc test showed that the 5.0 mg/kg dose was significantly different than vehicle 
(p < 0.05). For number of responses (Figure 11, bottom panel), S(+)-ketamine did not produce a 
significant main effect of dose [F(2,16)=2.45,p= 0.06]. A dose of 10.0 mg/kg of S(+)-ketamine 
was administered to six mice but induced cataleptic behavior so further testing with this dose 
was discontinued.  
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Figure 9. Effects of racemic ketamine on mean (+SEM) number of reinforcers (top; n=12) and 
number of responses (bottom; n=12). See Figure 4 for other details. 
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Figure 10. Effects of R(-)-ketamine on mean (+SEM) number of reinforcers (top; n=9) and 
number of responses (bottom; n=9). See Figure 4 for other details. 
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Figure 11. Effects of S(+)-ketamine on mean (+SEM) number of reinforcers (top; n=9) and 
number of responses (bottom; n=9). See Figure 4 for other details. 
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IRT distributions: For IRT distributions, the highest dose for test drugs that produced a 
significant effect (or change) for reinforcers and responses were compared to vehicle.  
Imipramine and MK-801 IRTs: For imipramine (Figure 12, top panel), 17.8 mg/kg did not 
produce a significant shift in the IRT distribution compared to vehicle (p > 0.05) although there 
was a slight right-ward shift for imipramine. For MK-801(Figure 12, bottom panel), 0.1 mg/kg 
did not produce a significant shift in the IRT distribution compared to vehicle (p > 0.05)although 
there was a slight left-ward shift for MK-801.  
Racemic amisulpride and its enantiomers IRTs: The 56.0 mg/kg dose of racemic amisulpride 
(figure 13, top panel) did not produce a significant shift in the IRT distribution, although there 
was a slight right-ward shift in the IRT distribution (p > 0.05). R(+)-amisulpride (32 mg/kg; 
figure 13, middle panel) and S(-)-amisulpride (10.0 mg/kg; figure 13, bottom panel) also did not 
produce a significant shift in the IRT distribution (p > 0.05).  
Racemic ketamine and its enantiomers: The 56.0 mg/kg dose of racemic ketamine (Figure 14, 
top panel) did not produce a significant shift in the IRT distribution (p > 0.05). The enantiomers 
R(-)-ketamine (10.0 mg/kg; figure 14, middle panel) and S(+)-ketamine (5.0 mg/kg; Figure 14, 
bottom panel) also did not produce a significant shift in the IRT distribution (p > 0.05).   
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Figure 12. IRT Distributions are shown for imipramine (top panel) and for MK-801 (bottom 
panel). 
  
40 
 
 
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
R a c e m i c  A m i s u l p r i d e  I R T  D i s t r i b u t i o n
I R T  D u r a t i o n  ( 6 - s e c  b i n )
R
e
la
t
iv
e
  
F
r
e
q
u
e
n
c
y
V E H
5 6 . 0  m g / k g
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
R ( + ) - A m i s u l p r i d e  D i s t r i b u t i o n
I R T  D u r a t i o n  ( 6 - s e c  b i n )
R
e
la
t
iv
e
  
F
r
e
q
u
e
n
c
y
V E H
3 2 . 0  m g / k g
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 2
0 . 4
0 . 6
S ( - ) - A m i u l p r i d e  I R T  D i s t r i b u t i o n
I R T  D u r a t i o n  ( 6 - s e c  b i n )
R
e
la
t
iv
e
  
F
r
e
q
u
e
n
c
y
V E H
1 0 . 0  m g / k g
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
0 . 5
R a c e m i c  K e t a m i n e  I R T  D i s t r i b u t i o n
I R T  D u r a t i o n  ( 6 - s e c  b i n )
R
e
la
t
i
v
e
  
F
r
e
q
u
e
n
c
y
V E H
1 0 . 0  m g / k g
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
0 . 5
R ( - ) - K e t a m i n e  I R T  D i s t r i b u t i o n
V E H
1 0 . 0  m g / k g
B u r s t 1 8 3 6 5 4 7 2 9 0 1 0 8 1 2 6 1 4 4
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
0 . 5
S ( + ) - K e t a m i n e  I R T  D i s t r i b u t i o n
V E H
5 . 0  m g / k g
 
Figure 13. IRT Distributions are shown for racemic amisulpride (left top panel), for R(+)-
amisulpride (left middle panel), and for S(-)-amisulpride (left bottom panel), racemic ketamine 
(right top panel), R(-)-ketamine (right middle panel), and S(+)-ketamine (right bottom panel).  
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Discussion 
The aim of the present study was to determine whether the enantiomers for ketamine and 
amisulpride produced antidepressant-like effects in a manner similar to their parent compounds 
using the differential-reinforcement-of-low-rate 72-sec task. Consistent with previous findings in 
the literature, we hypothesized that amisulpride and S(-)-amisulpride, but not R(+)-amisulpride, 
would produce antidepressant-like effects, while all formulations of ketamine would produce 
antidepressant effects. Racemic amisulpride and S(-)-amisulpride, but not R(+)-amisulpride, 
produced an antidepressant-like effect, evidenced by a significant increase in the number of 
reinforcers and a significant decrease in the number of responses. Racemic ketamine and R(-)-
ketamine significantly increased the number of reinforcers and decreased the number of 
responses, while S(+)-ketamine significantly increased the number ofreinforcers, but did not 
decrease the number of responses (at the doses tested). Overall, these results indicate that 
racemic amisulpride, S(-)-amisulpride, and all formulations of ketamine demonstrate 
antidepressant-like effects as assessed in the DRL 72-sec task and may be useful in a clinical 
context. If either of the ketamine isomers can be shown to produce fewer psychotomimetic 
effects in humans, then the isomers may offer a significant clinical advantage over the parent 
compound ketamine. Regarding amisulpride, the present results indicate that the S(+) isomer is 
the active component of the parent drug and that the R(-) isomer is relatively inactive at the doses 
tested.  
Theantidepressant-like effects observed with racemic ketamine and its isomers in the 
present study are consistent with previous research that showed the 10.0 mg/kg dose of racemic 
ketamine and R(-)-ketamine produce antidepressant-like effects in several preclinical procedures 
used to assess antidepressant effects. For instance, Zhang et al. (2014) showed that all 
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formulations of ketamine produce antidepressant-like effects in the tail suspension test, forced 
swim test, and sucrose preference test.After establishing that neonatal dexamethasone exposure 
causes depression-like behavior in juvenile mice, Zhang et al. (2014) showed that both isomers 
for ketamine significantly attenuated the increase in immobility time in the tail suspension test 
and forced swim test at doses similar to those used in the present study.Another study showed 
that R(-)-ketamine produced greater potency and longer lasting antidepressant-like effects than 
did S(+)-ketamine in the social defeat stress and learned helplessness models of depression in 
mice (Yang et al., 2015). The present study results are also consistent with previous research in 
rats, which showed that ketamine, but not MK-801, produced antidepressant-like effects in the 
DRL 72-sec task; thus, demonstrating cross-species similarities in antidepressant activity for 
ketamine (Hillhouse & Porter, 2014). The current study results extend these findings in rats to a 
new species (mice) and to ketamine‘s stereoisomers. Taken together, these data suggest that all 
formulations of ketamine produce antidepressant-like effects and may be useful in a clinical 
context.  
The antidepressant-like effects observed with racemic amisulpride are in agreement with 
previous preclinical studies in male Wistar rats that showed racemic amisulpride (1 and 3 mg/kg) 
produced antidepressant-like effects in the forced swim test while doses of 5 and 10 mg/kg 
elicited antidepressant-like effects in the chronic mild stress model (Papp & Wieronska, 2000). 
However, it is not immediately known why low doses in that study produced an antidepressant-
like effect; whereas, our study found that a dose of 56.0 mg/kg of racemic amisulpride produced 
the strongest antidepressant-like effect. These differences in dose effects may be attributable to 
pharmacokinetic differences between male C57BL/6 mice and male Wistar rats. Furthermore, to 
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the best of our knowledge, this is the first preclinical study to investigate the antidepressant-like 
activity of amisulpride‘s stereoisomers.  
 A variety of monoaminergic compounds have been assessed in the DRL 72-sec task and 
have shown mixed results in terms of their antidepressant-like effects. For instance, drugs that 
function as norepinephrine transporter inhibitors (Marek et al., 1988; Wong et al., 2000; 
Dekeyne et al., 2002), tricyclic antidepressants (O‘Donnell and Seiden, 1983; Marek and Seiden, 
1988; Richards and Seiden, 1991; Richards et al., 1993; Cousins and Seiden, 2000; Ardayfio et 
al., 2008; Hillhouse and Porter, 2014), serotonin transporter inhibitors (Richards et al., 1993; 
Balcells-Olivero et al., 1998; Sokolowski and Seiden, 1999; Cousins and Seiden, 2000), 5-HT2A 
receptor antagonists (Marek and Seiden, 1988; Marek et al., 1989, 2005), and 5-HT2C receptor 
agonists (Martin et al., 1998) have all been shown to produce antidepressant-like effects in the 
DRL 72-sec task and most of these drugs produce antidepressant effects in humans. Amisulpride 
is an atypical antipsychotic that functions primarily as a dopamine D2 and D3 receptor antagonist, 
but has been shown to be a potent 5-HT7 receptor antagonist (Abbas et al., 2000). Abbas et al. 
(2000) argue that the 5-HT7 receptor antagonist effects of amisulpride are responsible for its 
antidepressant-like effects, but further research is needed to confirm that hypothesis. Other 
studies have shown that, at low doses, amisulpride‘s antidepressant effects may be related to 
presynaptic antagonism of DA receptors, while its antipsychotic effects are related to 
postsynaptic antagonism. At high doses (40-80 mg/kg), amisulpride blocks postsynaptic 
dopaminergic receptors similar to that seen with other antipsychotic medications; however, at 
low doses (˂10 mg/kg) amisulpride increases dopaminergic transmission by blocking 
autoreceptors on the presynaptic terminals (Möller, 2003). Presynaptic blockade leads to 
increased dopaminergic transmission (Sanger, Perrault, Schoemaker, & Scatton, 1999; 
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Schoemaker et al., 1997), and it has been hypothesized that increaseddopamine release via 
amisulpride‘s antagonism of presynaptic autoreceptors may beresponsible for its therapeutic 
effects in alleviating depression. However, in the DRL 72-sec task, antipsychotics have mixed 
effects (for a review, see O‘Donnell et al., 2005 and Marek et al., 2016). Our findings in the 
present study showing that racemic amisulpride and S(-)-amisulpride, but not R(+)-amisulpride, 
produce antidepressant-like effects are likely due to a number of pharmacodynamic differences 
between the isomers. First, S(-)-amisulpride is approximately twice as potent as racemic 
amisulpride and 20-50 times more potent than R(+)-amisulpride at dopamine D2 and D3 
receptors, while R(+)-amisulpride is twice as potent as racemic amisulpride and four times more 
potent than S(-)-amisulpride at alpha2-adrenoreceptors (Marchese et al., 2002). Second, while 
both racemic amisulpride and R(+)-amisulpride have been shown to generalize to the S(-)-
amisulpride stimulus in a drug discrimination procedure (Donahue et al., 2014), S(-)-amisulpride 
was about three times more potent than racemic amisulpride and ten times more potent than R(-)-
amisulpride, suggesting that its therapeutic effects may be particularly sensitive to dose-related 
factors.  
In contrast to the wide variety of monoaminergic drugs tested in the DRL 72-sec task, the 
effects of glutamatergic drugs in this procedure is less understood. Hillhouse and Porter (2014a) 
showed that ketamine, but not MK-801, produced antidepressant-like effects in rats, as 
evidenced by an increase in reinforcers, decrease in responses, and a rightward shift in the IRT 
distribution for ketamine (MK-801 produced opposite results). The lack of antidepressant-like 
effects for MK-801 were also demonstrated by Ardayfio et al. (2008). Furthermore, Hillhouse et 
al., (2014b) also showed that phencyclidine (from which ketamine is derived) increased 
reinforcers and decreased responses without shifting the peak location of the IRT distribution, 
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suggesting phencyclidine produces weaker antidepressant-like effects as compared to ketamine. 
While the effects of glutamatergic drugs in the DRL 72-sec task are yet to be fully established, a 
recent review by Marek et al., (2016) proposed that the DRL procedure is not simply an 
antidepressant screening task. Rather, they posited that the wide range of behavior exhibited in 
the DRL 72-sec task in response to different drugs is due to an interaction between impulsivity 
and cognitive functions that may be disturbed in depressed patients, particularly the severely 
depressed. This hypothesis is in agreement with clinical studies that have shown ketamine is 
particularly useful in those who are severely depressed, while the antidepressant-like effects of 
drugs used to treat less severe forms of depression (dysthymia) may not be as apparent in the 
DRL 72-sec task.  
In conclusion, the present study results are in agreement with both the preclinical and 
clinical literature demonstrating that racemic amisulpride and its S(-) isomer and ketamine and 
its isomers S(+) and R(-) produce antidepressant-like effects in a mannersimilar to the tricyclic 
antidepressant imipramine. In contrast to ketamine, the more selective and higher affinity 
NMDA receptor antagonist MK-801 failed to produce an antidepressant-like effect in the DRL 
72-sec task, but rather produced effects more similar to psychostimulant-like effects (also see 
Hillhouse and Porter 2014). It also should be noted that the IRT distributions for the drugs tested 
did not show the typical right-ward shifts associated with antidepressant-like drugs that have 
been tested in rats (see Hillhouse and Porter 2014) These data demonstrate that the 
antidepressant-like effects of ketamine and its isomers observed in the present study cannot be 
simply explained by noncompetitive antagonism of NMDA receptors and off-target mechanisms 
could be responsible for these effects. For instance, MK-801 is about 30-fold more selective for 
the NET, three-fold more selective for the SERT (Nishimura et al., 1998), and eight-fold more 
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selective for the kappa opioid receptor (Smith et al., 1987). Specifically, kappa opioid receptor 
agonists have been shown to produce dysphoria, hallucinations, and dissociation, which has 
limited their clinical usefulness; thus, the lack of antidepressant-like effects observed by MK-801 
in the present study could be due to stronger psychotomimetic effects compared to ketamine. In 
addition, the present study also established cross-species antidepressant-like effects in the DRL 
72-sec task in male C57/BL mice that complements the current literature that has predominantly 
used rats, suggesting that ketamine has robust antidepressant-like effects in preclinical animal 
models. Further studies using different glutamatergic and novel monoaminergic drugs with 
multimodal effects are warranted. Studies examining the differences between male and female 
subjects would also be pertinent, considering, in female rats, the FST elicited a significant 
decrease in serotonergic activity in the hypothalamus and a decrease in 5-HT1A mRNA levels, 
whereas 5-HT1A mRNA levels were increased in male rats (Drossopoulou et al., 2004). 
Furthermore, Liu and Gershenfeld (2001) demonstrated that female mice had longer durations of 
immobility across four different strains of mice compared to male mice. This discrepancy 
between male and female mice on antidepressant-like effects in preclinical models could be 
further understood by examining sex differences in the DRL 72-sec task. Finally, it must be 
noted that the current study and many of the previous preclinical studies in the literature have 
only studied the acute dosing effects of ketamine and other drugs in tasks designed to assess the 
antidepressant-like effects of drugs. Given that the clinical effects of antidepressants in humans 
are typically only evident after several weeks of repeated dosing, preclinical studies also need to 
address this issue. With repeated dosing regimens, it might be possible to show stronger 
antidepressant-like effects or show effects at lower doses than seen with acute dosing. In the 
present study there was a trend for the R(-)isomer of amisulpride to increase reinforcers up to the 
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32 mg/kg dose tested but it did not reach significance. It is possible that the antidepressant-like 
effects of amisulpride are only evident at lower doses and that repeated dosing may be required 
for those effects to be evident in this assay.Interestingly, the dose effect functions between the R 
and S enantiomers and the racemic form of both amisulpride and ketamine may have important 
implications for future testing of antidepressant-like effects. First, in agreement with previous 
literature, the S(-) isomer for amisulpride appears to be more critical for eliciting antidepressant-
like effects since a dose of 10.0 mg/kg produced a significant increase in reinforcers, while much 
higher doses of racemic amisulpride produced antidepressant-like effects and R(+)-amisulpride 
produced no antidepressant-like effects at the doses tested. Furthermore, while R(-)-ketamine 
produced a significant increase in reinforcers and a decrease in responses at the 10.0 mg/kg dose, 
S(+)-ketamine produced a significant increase in reinforcers at the 5.0 mg/kg dose. These data 
indicate that the R and Sketamine enantiomers may not be equally important for producing 
antidepressant-like effects. It would be interesting to conduct combination testing with the 
isomers of ketamine and amisulpride to determine the relative contributions of each isomer to the 
effects seen with the parent compounds. 
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